Sign up
PHVS

Pharvaris BV (NASDAQ: PHVS)

Healthcare · Biotechnology

$31.55−0.73 (−2.26%)

Last close · Nov 18, 2026 · NASDAQ USD

Set alert

The Quantellect read. PHVS fell 2.26% in the Nov 18 session to $31.55. The borrow fee is 0.28%. Descriptive summary of the data on this page, not a recommendation.

Relative valuation—

—

MomentumNeutral

RSI (14) 55.0 (overbought above 70, oversold below 30)

Trend—

—

Short interest5.8% of float

FINRA settlement Oct 30, 2026

PHVS price chart

Price $31.55 · As of Nov 18, 2026, 3:59 PM ET

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open
$32.24Nov 18, 2026 session
Previous close
$32.28Nov 17, 2026 close
Day range
$31.22 – $32.63Nov 18, 2026 session
52-week range—
Volume
390.16KNov 18, 2026 session
Average volume (30 calendar days)—
Market cap—
P/E (TTM)—
Forward P/E—
EPS (TTM)—
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—

Price history

PHVS · nasdaq · USD

Last completed session: Nov 17, 2026

Split-adjusted · volume in shares

Missing session: Nov 18, 2026

November 2026 · 12 completed sessions
DateOpenHighLowCloseChangeVolume
32.0032.4231.2932.28−0.16−0.493218%241,403
Open 32.00High 32.42Low 31.29
33.1934.4632.4432.44−0.92−2.757794%307,782
Open 33.19High 34.46Low 32.44
33.7934.277832.8533.36−0.47−1.389299%182,643
Open 33.79High 34.2778Low 32.85
33.5934.54533.0033.83−0.35−1.023991%376,268
Open 33.59High 34.545Low 33.00
34.0134.72533.81534.18+0.19+0.558988%421,746
Open 34.01High 34.725Low 33.815
34.1035.0533.2133.99−0.48−1.392515%745,421
Open 34.10High 35.05Low 33.21
34.8035.4734.0534.47+0.08+0.232626%638,333
Open 34.80High 35.47Low 34.05
32.8535.2132.27934.39+1.86+5.717799%405,107
Open 32.85High 35.21Low 32.279
34.3334.6632.5332.53−1.80−5.243227%932,848
Open 34.33High 34.66Low 32.53
35.0635.41533.0334.33−0.45−1.293847%311,377
Open 35.06High 35.415Low 33.03
33.9035.3033.9034.78+1.25+3.728005%577,201
Open 33.90High 35.30Low 33.90
33.6834.2132.9033.530.000.00%633,056
Open 33.68High 34.21Low 32.90

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

Change since Nov 17
Squeeze21Idle—
How the scores work →

Industry comparison

— · Industry comparison not available

Upcoming events

— · Upcoming events not available

Analyst consensus

— · Analyst consensus not available

Earnings history

— · Earnings history not available

Smart-money activity

In the last 60 days: 3 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.

DateTypeWhoActionAmountSource
Insider sellMonges VivianeSell$395.5KForm 4
Insider sellSchikan Johannes Gerardus Christiaan PetrusSell$29.0KForm 4
Insider sellNassif David W.Sell$218.8KForm 4
Insider sellLu PengSell$3.5MForm 4
Insider sellSchikan Johannes Gerardus Christiaan PetrusSell$7MForm 4
Insider sellBjork ElisabethSell$2.0MForm 4
Insider sellGlassman RobertSell$558.8KForm 4
Insider sellLesage AnneSell$765.5KForm 4
Insider sellAbele Stefan AndreasSell$54.9KForm 4
Insider sellAbele Stefan AndreasSell$1.7MForm 4
All smart-money activity →

News and press releases

All PHVS news →

Company profile

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in

CEO
Mr. Berndt Axel Edvard Modig CPA, M.B.A.
Headquarters
Zug, Switzerland
Employees
148
IPO date
Feb 5, 2021
Sector
Healthcare
Industry
Biotechnology

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.